[go: up one dir, main page]

ATE233278T1 - Herstellung von stabilen zink-insulinanalogen- kristallen - Google Patents

Herstellung von stabilen zink-insulinanalogen- kristallen

Info

Publication number
ATE233278T1
ATE233278T1 AT95304098T AT95304098T ATE233278T1 AT E233278 T1 ATE233278 T1 AT E233278T1 AT 95304098 T AT95304098 T AT 95304098T AT 95304098 T AT95304098 T AT 95304098T AT E233278 T1 ATE233278 T1 AT E233278T1
Authority
AT
Austria
Prior art keywords
production
insulin analog
zinc insulin
stable zinc
analog crystals
Prior art date
Application number
AT95304098T
Other languages
English (en)
Inventor
Jeffrey Clayton Baker
Nancy Delores Carter
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22990041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE233278(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE233278T1 publication Critical patent/ATE233278T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT95304098T 1994-06-16 1995-06-14 Herstellung von stabilen zink-insulinanalogen- kristallen ATE233278T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,647 US5504188A (en) 1994-06-16 1994-06-16 Preparation of stable zinc insulin analog crystals

Publications (1)

Publication Number Publication Date
ATE233278T1 true ATE233278T1 (de) 2003-03-15

Family

ID=22990041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95304098T ATE233278T1 (de) 1994-06-16 1995-06-14 Herstellung von stabilen zink-insulinanalogen- kristallen

Country Status (29)

Country Link
US (1) US5504188A (de)
EP (1) EP0692489B1 (de)
JP (1) JP3595607B2 (de)
KR (1) KR100369951B1 (de)
CN (1) CN1184234C (de)
AT (1) ATE233278T1 (de)
AU (1) AU697794B2 (de)
BR (1) BR9502798A (de)
CA (1) CA2151563C (de)
CO (1) CO4410205A1 (de)
CZ (1) CZ286066B6 (de)
DE (1) DE69529708T2 (de)
DK (1) DK0692489T3 (de)
ES (1) ES2188637T3 (de)
FI (1) FI952930L (de)
HU (1) HUT73495A (de)
IL (1) IL114152A (de)
IN (1) IN178919B (de)
MY (1) MY130551A (de)
NO (1) NO952334L (de)
NZ (1) NZ272358A (de)
PE (1) PE21896A1 (de)
PL (1) PL180968B1 (de)
RO (1) RO113529B1 (de)
RU (1) RU2156257C2 (de)
SI (1) SI0692489T1 (de)
TW (1) TW379228B (de)
YU (1) YU39595A (de)
ZA (1) ZA954942B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
US5631347A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
ATE220555T1 (de) * 1997-03-20 2002-08-15 Novo Nordisk As Verfahren zur herstellung eines therapeutischen puders durch copräzipitation von insulin und einem absorptionsverstärker
JP2001522793A (ja) * 1997-11-12 2001-11-20 アルザ コーポレイション 経皮電気輸送送達用の緩衝処理された薬物処方物
RU2205188C2 (ru) 1998-06-30 2003-05-27 Ново Нордиск А/С Затравочные кристаллы для получения пептидов или протеинов
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
ATE277630T1 (de) * 1998-10-16 2004-10-15 Novo Nordisk As Stabile konzentrierte insulin präparationen zur pulmonaren verabreichung
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
BR9914568A (pt) * 1998-10-16 2001-07-03 Novo Nordisk As Formulação aquosa de insulina, preparação de insulina e método de tratamento de diabetes do tipo i ou do tipo ii
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
EP1801120A1 (de) * 2001-02-09 2007-06-27 Genentech, Inc. Co-kristalliner IGF-1-Komplex und Verfahren zur Identifizierung von indirekten IGF-1-Agonisten unter Verwendung desselben
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
EP1787982B1 (de) 2003-04-11 2010-05-12 High Point Pharmaceuticals, LLC Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
CN102784386A (zh) 2003-11-20 2012-11-21 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
RU2499795C2 (ru) 2005-07-04 2013-11-27 Хай Пойнт Фармасьютикалс, ЛЛС Антагонисты гистаминовых н3-рецепторов
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
JP5198280B2 (ja) 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
WO2007104786A1 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Mixtures of amylin and insulin
JP2009531376A (ja) 2006-03-28 2009-09-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒスタミンｈ３受容体活性を有するベンゾチアゾール
US8927015B2 (en) * 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US7998999B2 (en) 2006-04-24 2011-08-16 Eli Lilly And Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
PT2079732E (pt) 2006-05-29 2012-02-02 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)- piridazina, os seus sais e solvatos e a sua utilização a título de antagonista do receptor h3 de histamina
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2514406A1 (de) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontan dispergierbare Vorkonzentrate mit einem Peptidwirkstoff in einem festen oder halbfesten Träger
EP2497462A1 (de) 2007-06-01 2012-09-12 Novo Nordisk A/S Stabile nichtwässrige pharmazeutische Zusammensetzungen
JP5552046B2 (ja) * 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
ES2664822T3 (es) * 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
EP2408808A4 (de) 2009-03-20 2015-05-06 Smartcells Inc Terminal-funktionalisierte konjugate und ihre verwendung
PL2464655T3 (pl) * 2009-08-11 2017-08-31 Biocon Limited Procesy chromatograficzne
CN103459417B (zh) 2011-02-01 2018-04-10 诺沃—诺迪斯克有限公司 胰岛素的纯化
WO2012104834A1 (en) 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
WO2014088836A1 (en) 2012-12-03 2014-06-12 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
EP2970124B1 (de) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondriale aldehyd-dehydrogenase-2-modulatoren und verfahren zur verwendung davon
CN103342746B (zh) * 2013-07-26 2014-07-30 珠海联邦制药股份有限公司 一种制备稳定的门冬胰岛素结晶的方法
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP2990033A1 (de) * 2014-08-26 2016-03-02 Carlina Technologies Verfahren aus Nanoausfällung von niedrige molekulargewichte Proteinen und Peptiden
EP3185887B1 (de) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Verfahren zur herstellung von kristallinem insulin oder insulin-analog-zusammensetzungen
CN104193819B (zh) * 2014-09-03 2017-05-17 韩飞 胰岛素二聚体晶体的合成和保存方法
CN104761632A (zh) * 2015-04-14 2015-07-08 珠海联邦制药股份有限公司 一种地特胰岛素结晶的制备方法及应用
CN106117345B (zh) * 2015-05-05 2020-11-24 宜昌东阳光长江药业股份有限公司 一种制备甘精胰岛素结晶的方法
CN104892749B (zh) * 2015-06-16 2019-02-05 珠海联邦制药股份有限公司 一种德谷胰岛素结晶的制备方法及应用
CN105753966A (zh) * 2016-05-05 2016-07-13 通化东宝药业股份有限公司 一种重组人胰岛素结晶的制备方法
EP3740212A4 (de) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. Konjugatbasierte systeme für kontrollierte insulinabgabe
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
JP2023520049A (ja) 2020-03-31 2023-05-15 プロトマー・テクノロジーズ・インコーポレイテッド 隣接ジオールに対する選択的応答性のためのコンジュゲート
JP2024500284A (ja) 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品
TW202409070A (zh) 2022-05-18 2024-03-01 美商普羅托莫科技公司 芳族含硼化合物及相關胰島素類似物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE533298A (de) *
BE533252A (de) *
BE515508A (de) *
US2143590A (en) * 1936-09-26 1939-01-10 Univ Alberta Insulin preparation and process of producing crystals of insulin
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2920104A (en) 1958-07-01 1960-01-05 Vanderbilt Co R T Stabilized solutions of a dithiocarbamate
US3719655A (en) * 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
KR900701842A (ko) * 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29

Also Published As

Publication number Publication date
DK0692489T3 (da) 2003-03-31
CN1184234C (zh) 2005-01-12
JP3595607B2 (ja) 2004-12-02
NO952334L (no) 1995-12-18
FI952930L (fi) 1995-12-17
ZA954942B (en) 1996-12-17
KR100369951B1 (ko) 2003-03-28
CZ286066B6 (cs) 2000-01-12
YU39595A (sh) 1997-08-22
PL309099A1 (en) 1995-12-27
RU2156257C2 (ru) 2000-09-20
CA2151563C (en) 2007-08-07
CA2151563A1 (en) 1995-12-17
AU697794B2 (en) 1998-10-15
US5504188A (en) 1996-04-02
HU9501715D0 (en) 1995-08-28
JPH08169899A (ja) 1996-07-02
TW379228B (en) 2000-01-11
IL114152A (en) 1999-12-31
CZ154195A3 (en) 1996-02-14
MY130551A (en) 2007-06-29
CO4410205A1 (es) 1997-01-09
SI0692489T1 (en) 2003-06-30
RU95110107A (ru) 1997-05-10
PL180968B1 (pl) 2001-05-31
HUT73495A (en) 1996-08-28
PE21896A1 (es) 1996-06-15
FI952930A0 (fi) 1995-06-14
EP0692489B1 (de) 2003-02-26
EP0692489A1 (de) 1996-01-17
RO113529B1 (ro) 1998-08-28
NO952334D0 (no) 1995-06-13
NZ272358A (en) 1996-12-20
IN178919B (de) 1997-07-19
DE69529708D1 (de) 2003-04-03
IL114152A0 (en) 1995-10-31
DE69529708T2 (de) 2003-10-16
CN1128271A (zh) 1996-08-07
KR960000922A (ko) 1996-01-25
BR9502798A (pt) 1996-06-04
ES2188637T3 (es) 2003-07-01
AU2168195A (en) 1996-01-04

Similar Documents

Publication Publication Date Title
ATE233278T1 (de) Herstellung von stabilen zink-insulinanalogen- kristallen
DE69013024D1 (de) Flüssigkristallpigment, Methode zur Herstellung und Verwendung in Bekleidungen.
ATE295745T1 (de) Hyaluronsäure-gel, verfahren zur dessen herstellung und hyaluronsäure-gel enthaltendes medizinisches material
ATE164184T1 (de) Expression von menschlichen serum-albuminen in pichia pastoris
ES2095592T3 (es) Filtro sanguineo perfeccionado eventualmente resorbible.
ATE101620T1 (de) Mini-proinsulin, seine herstellung und verwendung.
DE69208418D1 (de) Verfahren und Anlage zur gemischten Herstellung von Sauerstoff hoher und niederer Reinheit
EP0190018A3 (en) Use of transforming growth factor to promote wound healing and composition therefor
DE69003000D1 (de) Verfahren zur kontinuierlichen Herstellung von Polyethylenmaterial mit erhöhter Stärke und hohem Elastizitätsmodul.
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
DE69514889D1 (de) Verfahren zur Herstellung von optisch aktiven 2-Hydroxysäure und 2-Hydroxyamid
DE69318909D1 (de) Verfahren zur Herstellung von menschlichem Wachstumshormon
DE68919282D1 (de) Verfahren zur Herstellung von Cephalosporin und Zwischenverbindungen.
DE69330506D1 (de) Eintopfverfahren zur Herstellung von Pergolid
DE69027577D1 (de) Verwendung von Benzothiazepinen zur Herstellung von Arzneimitteln zur Behandlung von epileptischen Anfällen
TH20759A (th) การเตรียมผลึกคล้ายอินซูลินกับสังกะสีที่เสถียร
HUT48907A (en) Process for production of small peptides linked to 1,4 receptors with immunogene effect and medical preparatives containing these substances
UA19964A (uk) Спосіб лікуваhhя трофічhих виразок у хворих цукровим діабетом

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0692489

Country of ref document: EP

REN Ceased due to non-payment of the annual fee